ArticleSurgical case reports2026
Spindle Cell (Metaplastic) Carcinoma of the Breast Showing No Clinical Benefit with Pembrolizumab-Based Neoadjuvant Chemoimmunotherapy.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetaplastic carcinoma (MC) of the breast is a rare subtype that is frequently chemoresistant, and clinical evidence for immune checkpoint inhibitor (ICI) therapy remains limited. Here, we report a case of spindle cell carcinoma (SpCC) MC showing primary resistance to neoadjuvant chemo-immunotherapy and describe features associated with the tumor immune microenvironment. CASE PRESENTATION: A woman with a 10-year history of a left breast mass presented with rapid enlargement to approximately 7 cm. Core needle biopsy revealed SpCC that was negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, with a high Ki-67 labeling index. Imaging suggested ipsilateral axillary nodal involvement, and neoadjuvant pembrolizumab combined with platinum/taxane chemotherapy was initiated. However, after 2 cycles, the tumor further enlarged with ulceration and protrusion from the prior biopsy site, consistent with progressive disease, and the patient underwent total mastectomy with axillary dissection. Histologically, the tumor consisted of high-grade atypical spindle cells with necrosis and minimal treatment effect. Immunohistochemistry demonstrated strong expression of programmed death-ligand 1 in both tumor and immune cells and increased CD8+ T-cell infiltration after therapy. By contrast, tumor cells showed significantly downregulated human leukocyte antigen (HLA)-A/B/C and β2-microglobulin, suggesting impaired antigen presentation. Increased CD163/CD204/triggering receptor expressed on myeloid cells 2-positive tumor-associated macrophages and focal transforming growth factor-β expression were also observed.
conclusionsThese findings suggest that HLA class I downregulation may contribute to ICI resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.